Carpenter, E. L. & Mossé, Y. P. ( 2012) Targeting ALK in neuroblastoma—preclinical and clinical advancements

Jul 13, 2014

60 likes | 353 Views

Figure 2 Timeline depicting the milestones leading to the clinical testing of the ALK inhibitor crizotinib targeting the full-length ALK in neuroblastoma (above) and translocated ALK in non-small-cell lung cancer (below) .

beck

Download Presentation

Carpenter, E. L. & Mossé, Y. P. ( 2012) Targeting ALK in neuroblastoma—preclinical and clinical advancements

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Figure 2Timeline depicting the milestones leading to the clinical testing of the ALK inhibitor crizotinib targeting the full-length ALK in neuroblastoma (above) and translocated ALK in non-small-cell lung cancer (below) Carpenter, E. L. & Mossé, Y. P. (2012) Targeting ALK in neuroblastoma—preclinical and clinical advancements Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2012.72